Merck Statement on GARDASIL®
- Details
- Category: Merck
Merck (NYSE:MRK), known as MSD outside the United States and Canada, issued the following statement on GARDASIL® [Human Papillomavirus Quadrivalent (Types 6, 11, 16 and 18) Vaccine, Recombinant], Merck's vaccine to protect against certain diseases caused by Human Papillomavirus (HPV) types 6, 11, 16 and 18.
Lilly Invests $30 Million in Partnership to Address Non-Communicable Diseases
- Details
- Category: Eli Lilly and Company
Eli Lilly and Company announced a $30 million commitment over five years to fight the rising burden of non-communicable diseases in developing nations.
Boehringer Ingelheim and EFSD collaborate to support diabetes research in Europe
- Details
- Category: Boehringer Ingelheim
Boehringer Ingelheim and the European Foundation for the Study of Diabetes (EFSD) today announced a new partnership to establish a €2.5 million research grant programme, encouraging diabetes research over the next three years.
Novartis increases growth potential through integration of Alcon
- Details
- Category: Novartis
Novartis presented an update on its long-term strategy, performance and vision for continued sustainable growth and gave an in-depth overview on the unique position and business model of the new Alcon Division.
Initiation of Lantus leads to better glycemic control at similar weight gain
- Details
- Category: Sanofi
Sanofi (EURONEXT: SAN and NYSE: SNY) announced data that demonstrates that initiating Lantus® (insulin glargine [rDNA origin] injection) in type 2 diabetes patients leads to better glycemic control and comparable and modest weight gain versus a comparator group consisting of other insulins, oral antidiabetics (OADs) and dietary changes.
Roche named Dow Jones Sustainability Index leader in healthcare for third consecutive year
- Details
- Category: Roche
Roche (SIX: RO, ROG; OTCQX: RHHBY) has been recognized as the most sustainable healthcare company globally in the Dow Jones Sustainability Index (DJSI), for the third year in a row. The DJSI World and DJSI Europe Indexes track the performance of the leading sustainability companies based on environmental, social and economic performance.
Bristol-Myers Squibb Completes Acquisition of Amira Pharmaceuticals
- Details
- Category: Bristol-Myers Squibb
Bristol-Myers Squibb Company (NYSE: BMY) has completed its previously announced acquisition of privately held Amira Pharmaceuticals, Inc., a small-molecule pharmaceutical company focused on the discovery and early development of new drugs to treat inflammatory and fibrotic diseases.
More Pharma News ...
- GSK awarded contract by BARDA to support research on potential novel antibiotic
- Bayer Confident in Results of ROCKET AF Study
- Roche’s Tarceva receives European approval for first-line use in a genetically distinct type of lung cancer
- Novartis drug Afinitor® gains EU approval to treat patients with advanced pancreatic neuroendocrine tumors
- AstraZeneca announces top-line results from SATURN study
- Bayer Healthcare to acquire Pathway Medical Technologies
- Daiichi Sankyo & Ranbaxy Announce a New Social Contribution Initiative